Vanderbilt TB Center News

RePORT-Brazil Investigators at CROI 2024

The 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver was attended by investigators from RePORT-Brazil, including presentations on recent findings and articles.   Poster Presentations: Dr. Gustavo Amorim, PhD - "Estimating Optimal Anti-TB Drug Concentrations in a Prospective, Observational Cohort in Brazil" Dr. Felipe Ridolfi, PhD, MD - “Pharmacogenetic Associations With HIV-1 Virologic Suppression Among Patients with TB/HIV in Brazil”

RePORT-Brazil in the Spotlight - CID Article

A recently publication in the journal Clinical Infectious Diseases is catching attention. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort  was published by the RePORT-Brazil consortium, with authorship being led by the team at the Fundação de Medicina Tropical in Manaus, Amazonas, Brazil.  

TB Center welcomes 1st Cohort of RePORT-Brazil Advanced Career Training (ReACT) Fellows

The Regional Prospective Observational Research in Tuberculosis - Brazil (RePORT-Brazil) network is pleased to announce its 1st Cohort of Fellows for the RePORT-Brazil Advanced Career Training (ReACT) program. Strategic Aim 3 of the recently renewed RePORT-Brazil Phase 2 grant (NIH U01AI172064-01), focuses on the development of a fellowship program for the advancement of early-career Brazilian scientists. The program provides funding for pilot projects in TB research, mentorship, and access to data and specimens collected throughout Phase 1 of the project.

VTC Hosts TB/HIV R01 Meeting

Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our TB/HIV grant "Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis" (NIH R01AI120790-04). The event, which took place on April 26th and 27th, included presentations on the results and findings of each working group, breakout sessions, and discussions on future steps to be taken and larger goals of the research.

VUMC lands Grant to build top-line Biosafety Facility

Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. When the renovation of about 3,500 square feet of existing space is completed, the facility will include three BSL3 suites with separate entrances and seven procedure rooms capable of securely containing multiple organisms at the second-highest biosafety level.

VUMC investigators attend RePORT-International Annual Meeting

VUMC investigators and staff, Timothy Sterling, Yuri van der Heijden, Stephany Duda, Marina Figueiredo, Fernanda Mauri, Megan Turner, and Austin Katona; attended the annual RePORT International meeting that was held in Cape Town, South Africa, September 7 and 8, 2022. The meeting included all seven regions of RePORT: Brazil, China, South Africa, South Korea, India, Indonesia, and the Philippines. It was a successful meeting full of presentations and collaborative discussions.

WHO Global TB Report was released!

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.